Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Launched by DANA-FARBER CANCER INSTITUTE · Apr 4, 2025

Keywords

ClinConnect Summary

The iSTAND Trial is a clinical study designed to explore whether a 12-week exercise program can help improve heart health and reduce side effects from chemotherapy in patients with lymphoma. Specifically, this trial will look at how breaking up long periods of sitting with short bouts of activity can benefit those receiving certain chemotherapy treatments (R-CHOP or POLA-R-CHP). The goal is to find out if this approach is safe and effective for newly diagnosed lymphoma patients.

To participate, individuals must be at least 18 years old, have been diagnosed with lymphoma, and will be starting the specified chemotherapy treatments. They should also be engaging in no more than 60 minutes of structured exercise each week and must be cleared by their doctor to participate. Participants will need to travel to the Dana-Farber Cancer Institute for exercise sessions and data collection. This study only includes patients who can safely engage in the program, so those with certain health conditions or who exercise more than the allowed amount will not be eligible. Overall, the trial aims to help improve the quality of life for lymphoma patients during their treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
• • Patients diagnosed with lymphoma.
• • Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.
• • Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
• • Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.
• • Have physician clearance to participate in exercise.
• • Speak English.
• • Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.
• • Access to a phone that can receive text messages.
• Exclusion Criteria:
• • Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.
• • Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.
• • Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.
• • Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
• • Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.